Nuwellis, Inc. has entered into a definitive agreement to acquire all outstanding shares of Rendiatech Ltd., an Israeli-based medical technology company specializing in automated kidney function monitoring. The acquisition is intended to enhance Nuwellis’ cardiorenal portfolio by expanding its capabilities from therapeutic fluid removal into real-time renal monitoring. Following the completion of the transaction, Nuwellis plans to integrate Rendiatech’s Clarity™ system, which offers automated, continuous renal monitoring through precise urine-output measurement, into its existing commercial infrastructure. This move is expected to lay the groundwork for future advancements in urine-based analytics and broader kidney function assessment. The transaction has been approved by the boards of directors of both companies and is expected to close following customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.